Amgen (NASDAQ:AMGN) had its price target boosted by UBS AG from $121.00 to $124.00. UBS AG currently has a buy rating on the stock.
Accuray (NASDAQ:ARAY) had its price target increased by Dougherty & Co from $7.50 to $8.00. The firm currently has a buy rating on the stock.
Actuant Corp. (NYSE:ATU) had its price target boosted by Stifel Nicolaus from $39.00 to $42.00. They currently have a buy rating on the stock.
Audiocodes Limited (NASDAQ:AUDC) had its target price increased by Oppenheimer from $5.00 to $7.00. The firm currently has an outperform rating on the stock. The analysts wrote, “We raise our price target to $7 from $5 for the following reasons: 1) we expect voice-related Lync adoptions rates to accelerate into 2014; 2) visibility and backlog are growing; 3) we expect operating margin to meaningfully start expanding in 2014; 4) One Voice for Lync opportunity is just in its infancy; and 5) potential longer-term M&A. Put together, we believe AUDC strategy is an effective one and solid execution could bring multiple expansion. We do believe the stock has run a bit ahead of itself and we’d be buyers on any pullbacks. Our new $7 price target is based on 1.6x EV/sales on our 2014 estimates. Reiterate Outperform.”
Chico’s FAS (NYSE:CHS) had its target price trimmed by Oppenheimer from $18.00 to $16.00. Oppenheimer currently has a market perform rating on the stock. The analysts wrote, “With the stock lagging ahead of 2Q13 and short interest building, shares rallied despite across-the-board miss for the quarter (first negative comp at WHBM in 17 quarters) given commentary on qtd comps swinging to positive. While valuation got some catch-up, estimates are coming down (we are modeling flat EPS in ’13), and sales/gross margin comparisons are tough in 2H13. Growth story remains compelling with hsd growth some of the best levels in our space, although the bulk of growth is coming from Soma (which just comped msd vs. dd for the past 2+ years). Yesterday’s stock action could reflect inflection point in sentiment for our group as CHS was the first company to miss and trade up. Lowering PT to $16 from $18 on lowered estimates.”
Chico’s FAS (NYSE:CHS) had its price target trimmed by FBR Capital Markets from $17.00 to $16.00. FBR Capital Markets currently has a market perform rating on the stock.
eGain Communications (NASDAQ:EGAN) had its target price raised by Ladenburg Thalmann from $10.75 to $14.50. Ladenburg Thalmann currently has a buy rating on the stock.
Guess? (NYSE:GES) had its target price raised by Telsey Advisory Group from $28.00 to $30.00. Telsey Advisory Group currently has a not rated rating on the stock.
Heico Corp. (NYSE:HEI) had its target price raised by Stifel Nicolaus from $55.00 to $65.00. Stifel Nicolaus currently has a buy rating on the stock.
Monolithic Power Systems (NASDAQ:MPWR) had its target price raised by Stifel Nicolaus from $32.00 to $34.00. Stifel Nicolaus currently has a buy rating on the stock.
Matador Resources (NASDAQ:MTDR) had its price target raised by Howard Weil from $13.00 to $21.00. Howard Weil currently has a sector outperform rating on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) was given a $25.00 target price by analysts at Deutsche Bank. The firm currently has a a buy rating on the stock. The analysts wrote, “Over the next 12 months we see four key catalysts that will provide upside to Neurocrine shares: Kinect Ph2, Kinect2 Ph2, Kinect safety, & Elagolix ph3 topline results. We also believe the opportunity for Elagolix in uterine fibroids (UF) is underappreciated. We have increased our probabilities for Elagolix in endometriosis (75% to 85%), VMAT2 (25% to 50%) to reflect trial successes over next 12 mo & raised Elagolix UF estimates. Maintain Buy.”
Fresh Market (NYSE:TFM) had its target price increased by Goldman Sachs Group Inc. to $65.00.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.